Immudapt-S 360 Tablet DR contains Mycophenolate sodium 360 mg, an immunosuppressive agent primarily indicated for the prevention of organ transplant rejection. Mycophenolate sodium acts by selectively inhibiting inosine monophosphate dehydrogenase, a key enzyme in the de novo synthesis of guanine nucleotides, thereby suppressing the proliferation of T and B lymphocytes. This mechanism reduces the immune response against transplanted organs, enhancing graft survival. The delayed-release (DR) formulation of Immudapt-S 360 is designed to minimize gastrointestinal side effects by releasing the active ingredient in the small intestine rather than the stomach. It is commonly prescribed in combination with other immunosuppressants such as cyclosporine and corticosteroids. Dosage and administration should be individualized based on the patient’s clinical condition, organ type, and concomitant therapies. Common adverse effects include gastrointestinal disturbances, leukopenia, anemia, and increased susceptibility to infections. Regular monitoring of complete blood counts and renal function is recommended during therapy. Caution is advised in patients with active infections or hematologic abnormalities. Immudapt-S 360 should be used under strict medical supervision, ensuring adherence to recommended dosing schedules to optimize therapeutic outcomes and minimize potential risks associated with immunosuppression.